Paper217398
Effects of Corynebacterium parvum on murine myeloid leukaemia.
Bjornsson S and 2 others. Br J Cancer, 1978. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Effects of Corynebacterium parvum on murine myeloid leukaemia. Papers, record 217398. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/217398
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid | Major topic |
| Propionibacterium acnes | Major topic |
| Animals | |
| Female | |
| Immunotherapy | |
| Leukemia, Experimental | |
| Liver | |
| Lung | |
| Mice | |
| Mice, Inbred Strains | |
| Necrosis | |
| Neoplasm Transplantation | |
| Polyvinylpyridine N-Oxide | |
| Silicon Dioxide | |
| Spleen | |
| Transplantation, Homologous |
Source PubMed
References18
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 271044 | Murine myeloid leukemia: I. Pathophysiology and drug sensitivity. | Cancer Treat Rep | 1977 | https://conductscience.org/library/papers/271044 | PubMed |
| 2 | 1009517 | Effects of Corynebacterium parvum alone and in combination with adriamycin in experimental tumor systems. | Cancer Treat Rep | 1976 | https://conductscience.org/library/papers/1009517 | PubMed |
| 3 | 4620441 | Corynebacterium parvum as an immunotherapeutic anticancer agent. | Semin Oncol | 1974 | https://conductscience.org/library/papers/4620441 | PubMed |
| 4 | 200763 | Abrogation of antitumor effects of Corynebacterium parvum and BCG by antimacrophage agents: brief communication. | J Natl Cancer Inst | 1977 | https://conductscience.org/library/papers/200763 | PubMed |
| 5 | 203549 | Natural cell-mediated cytotoxicity in rats. III. Effects of immunopharmacologic treatments on natural reactivity and on reactivity augmented by polyinosinic-polycytidylic acid. | Int J Cancer | 1978 | https://conductscience.org/library/papers/203549 | PubMed |
| 6 | 193547 | Immunological mechanisms in metastatic spread and the antimetastatic effects of C. parvum. | Br J Cancer | 1977 | https://conductscience.org/library/papers/193547 | PubMed |
| 7 | 330869 | In vivo transfer of antitumor activity by peritoneal exudate cells from mice treated with Corynebacterium parvum: reduced effect in irradiated recipients. | J Natl Cancer Inst | 1977 | https://conductscience.org/library/papers/330869 | PubMed |
| 8 | 627428 | Natural cell-mediated cytotoxicity in rats. II. In vivo augmentation of NK-cell activity. | Int J Cancer | 1978 | https://conductscience.org/library/papers/627428 | PubMed |
| 9 | 908026 | Local control and disease-free survival after treatment of a squamous cell carcinoma by Corynebacterium parvum and local irradiation. | Cancer Res | 1977 | https://conductscience.org/library/papers/908026 | PubMed |
| 10 | 889682 | Intravascular coagulation resulting from intravenous injection of C. parvum in mice. | Br J Cancer | 1977 | https://conductscience.org/library/papers/889682 | PubMed |
| 11 | 4369740 | Abrogation of resistance to bone marrow grafts by silica particles. Prevention of the silica effect by the macrophage stabilizer poly-2-vinylpyridine N-oxide. | J Immunol | 1974 | https://conductscience.org/library/papers/4369740 | PubMed |
| 12 | 4312660 | Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. | Br J Cancer | 1969 | https://conductscience.org/library/papers/4312660 | PubMed |
| 13 | 4213016 | Corynebacterium parvum as a therapeutic antitumor agent in mice. II. Local injection. | J Natl Cancer Inst | 1974 | https://conductscience.org/library/papers/4213016 | PubMed |
| 14 | 4213015 | Corynebacterium parvum as a therapeutic antitumor agent in mice. I. Systemic effects from intravenous injection. | J Natl Cancer Inst | 1974 | https://conductscience.org/library/papers/4213015 | PubMed |
| 15 | 813755 | The effect of gold salts on tumour immunity and its stimulation by Corynebacterium Parvum. | Br J Cancer | 1975 | https://conductscience.org/library/papers/813755 | PubMed |
| 16 | 947509 | Observations following Corynebacterium parvum administration to patients with advanced malignancy. a phase I study. | Cancer | 1976 | https://conductscience.org/library/papers/947509 | PubMed |
| 17 | 1206740 | Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. I. Variation in administration of both agents. | J Natl Cancer Inst | 1975 | https://conductscience.org/library/papers/1206740 | PubMed |
| 18 | 5435189 | Active immunotherapy with Corynebacterium parvum and chemotherapy in murine fibrosarcomas. | Br Med J | 1970 | https://conductscience.org/library/papers/5435189 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 6420046 | Adjuvant immune stimulation with Corynebacterium parvum during maintenance chemotherapy of acute myeloid leukemia. A prospective randomized study. | Cancer Immunol Immunother | 1983 | https://conductscience.org/library/papers/6420046 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/217398
GET https://conductscience.org/api/papers/v1/217398/authors